- Sales Grow to $163.5 million, Sets New Quarterly Record -
- Arthroscopy Sales Grow 7.3% -
UTICA, N.Y., July 25 /PRNewswire-FirstCall/ -- CONMED Corporation
(Nasdaq: CNMD) today announced financial results for the second quarter
ended June 30, 2006. Sales for the 2006 second quarter were $163.5 million
compared to $158.3 million in the second quarter of 2005. Net income
equaled $3.4 million, or $0.12 per diluted share for the quarter, compared
to $10.5 million, or $0.35 per diluted share in the second quarter of 2005,
based on a diluted weighted average share count of 28.3 million shares for
the quarter ended June 30, 2006.
Excluding transition charges related to an acquisition and other
unusual charges (see commentary below and attached reconciliation for
additional information), non-GAAP net income for the second quarter was
$6.6 million, or $0.23 per non-GAAP diluted share, compared to second
quarter 2005 non-GAAP net income of $13.4 million, or $0.45 per non-GAAP
diluted share. In January 2006, the Company adopted Statement of Financial
Accounting Standards No. 123R, "Share-Based Payment" ("SFAS 123R"), which
requires companies to recognize the cost of stock options and other
stock-based payments as compensation expense. As a result of adopting SFAS
123R, the diluted earnings per share and non-GAAP diluted earnings per
share were reduced by approximately $0.03 per share in the June 2006
quarter.
Mr. Joseph J. Corasanti, President and Chief Operating Officer, noted,
"We are pleased the positive sales momentum from the first quarter has
carried over to the second quarter of 2006, exceeding our expectations and
setting a record for quarterly sales. Our capital equipment business was
particularly strong growing 11% over the second quarter of 2005 due to
increases in video imaging products and electrosurgical generator sales.
These sales results are particularly impressive since the second quarter of
last year's sales were also exceptionally strong."
Sales outside the United States were $62.8 million in the second
quarter of 2006 growing 5.3% overall and 3.6% on a constant currency basis
compared to the second quarter of 2005. International sales grew to 38.4%
of the Company's total sales in the June 2006 quarter continuing the trend
for higher growth in international markets.
The Company's cash flow continued to be strong with cash from
operations totaling $27.5 million for the six months ended June, 2006. This
enabled the Company to reduce its senior credit lines and other borrowings
by $6.9 million. Additionally, the Company repurchased $7.8 million of its
common stock during the first six months of 2006.
Following is a summary of the Company's sales by product line for the
three months ended June 30, 2006 (in millions):
Three Months Ended June 30,
Constant
Currency
2005 2006 Growth Growth
(in millions)
Arthroscopy $54.8 $58.8 7.3% 6.1%
Powered Surgical
Instruments 33.9 33.3 -1.8% -2.9%
Electrosurgery 22.6 24.2 7.1% 7.1%
Endoscopic Technologies 15.0 14.7 -2.0% -2.0%
Endosurgery 12.9 13.3 3.1% 3.1%
Patient Care 19.1 19.2 0.5% 0.5%
$158.3 $163.5 3.3% 2.6%
As has been previously discussed, the Company's profitability in the
latter half of 2005 and in 2006 has been impacted by several factors
including increased costs of production caused by higher petroleum based
plastic raw materials and transportation, litigation costs, quality
initiatives, greater research and development expenditures, and higher
interest costs. Management has initiated a number of profit improvement
initiatives resulting in sequential operating margin improvement. For the
second quarter 2006, operating margin excluding acquisition and other
unusual charges, was 9.1% of sales compared to 7.5% in the fourth quarter
of 2005 and 8.5% in the first quarter of 2006.
Acquisition and Unusual Charges
As a result of the acquisition of Endoscopic Technologies, the Company
had been purchasing the finished goods of the product line from the former
owner until adequate safety stock had been accumulated to facilitate an
orderly transfer of the manufacturing process to the Company's facilities.
As of March 31, 2006 all of the required safety stock had been accumulated.
During the second quarter of 2006, manufacturing of the vast majority of
the products had begun, at least on a pilot run basis, in the Company's
facilities. However, first-in first-out (FIFO) inventory accounting
requires that the higher cost safety stock inventory be sold before the
expected lower-cost self-manufactured inventory is sold. The Company has
noted this difference in cost, as well as certain other costs associated
with the start-up of production, as a pro-forma adjustment to GAAP income
amounts.
In April 2006, the Company refinanced its debt, resulting in a reduced
interest rate and increased availability. The deferred financing fees
associated with the previous debt were written off in the second quarter of
2006 amounting to $678,000.
During the second quarter of 2006, the Company was notified that the
supplier of certain of its pulse oximetry products could no longer provide
product because of the settlement of a patent dispute with a third party.
Because the Company can no longer assure customers of a continuing supply
of these products, the Company has discontinued their marketing and charged
off inventory valued at $595,000. The discontinuation of these products is
not expected to have a material impact on the Company's sales or results of
operations. This matter does not affect the vast majority of the Company's
pulse oximetry products and also does not affect sales of its proprietary
Pro2(R) pulse oximetry line.
Six Month Results
For the six months ended June 30, 2006, CONMED reported revenues of
$321.9 million, a 2.5% increase from the $314.1 million in the first six
months of last year. Net income for the first six months of 2006 was $7.8
million, $0.27 per diluted share, compared to $21.3 million and $0.71 per
share in the first six months of 2005. Non-GAAP net income for the first
six months of 2006 was $12.5 million, or $0.44 per diluted share,
(excluding acquisition transition and other charges) compared to non-GAAP
net income of $26.9 million, or $0.90 per diluted share, for the six months
ended June 30, 2005 (please see attached schedule for full explanation of
transition and other charges). Adoption of SFAS 123R regarding expensing of
stock options and other stock-based payments in 2006 caused diluted
earnings per share and non- GAAP diluted earnings per share to be reduced
by $0.05 for the six months ended June 2006.
Following is a summary of the first six months of 2006 sales by product
line in millions of dollars:
Six Months Ended June 30,
Constant
Currency
2005 2006 Growth Growth
(in millions)
Arthroscopy $108.8 $113.5 4.3% 4.4%
Powered Surgical
Instruments 69.4 67.5 -2.7% -2.6%
Electrosurgery 43.5 47.5 9.2% 9.2%
Endoscopic Technologies 29.2 29.4 0.7% 0.7%
Endosurgery 25.2 25.2 0.0% 0.0%
Patient Care 38.0 38.8 2.1% 2.1%
$314.1 $321.9 2.5% 2.6%
Outlook
Mr. Corasanti concluded, "The Company's results for the second quarter
of 2006 exceeded our expectations for both sales and profitability. As a
result, we continue to believe that we are on track to achieve 5% organic
sales growth for 2006 compared to 2005 and that non-GAAP diluted earnings
per share should approximate $0.85 - $0.90 including the non-cash charge
for stock option and other share-based payments expense. We also continue
to believe that our operating margin in 2007 will improve to approximately
14% of sales as growing revenues leverage the Company's fixed-cost
structure and as we realize measures to improve margins and reduce costs."
For the third quarter 2006, CONMED anticipates revenues in the range of
$152 - $157 million and diluted earnings per share on a non-GAAP basis
(including SFAS 123R expense) of $0.16 - $0.20 per share.
Conference Call
The Company will webcast its second quarter 2006 conference call live
over the Internet on Tuesday, July 25, 2006 at 10:00 a.m. Eastern Time.
This broadcast can be accessed from CONMED's web site at
http://www.conmed.com. Replays of the call will be made available through
August 1, 2006.
CONMED Profile
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and monitoring. The
Company's products serve the clinical areas of arthroscopy, powered
surgical instruments, electrosurgery, cardiac monitoring disposables,
endosurgery and endoscopic technologies. They are used by surgeons and
physicians in a variety of specialties including orthopedics, general
surgery, gynecology, neurosurgery, and gastroenterology. Headquartered in
Utica, New York, the Company's 3,100 employees distribute its products
worldwide from several manufacturing locations.
Forward-Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. The Company believes that all forward-looking
statements made by it have a reasonable basis, but there can be no
assurance that management's expectations, beliefs or projections as
expressed in the forward-looking statements will actually occur or prove to
be correct. In addition to general industry and economic conditions,
factors that could cause actual results to differ materially from those
discussed in the forward-looking statements in this press release include,
but are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks relating
to forward-looking statements discussed in the Company's Annual Report on
Form 10-K for the fiscal year ended December 31, 2005; (iii) cyclical
purchasing patterns from customers, end-users and dealers; (iv) timely
release of new products, and acceptance of such new products by the market;
(v) the introduction of new products by competitors and other competitive
responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(in thousands except per share amounts)
(unaudited)
Three months ended Six months ended
June 30, June 30,
2005 2006 2005 2006
Net sales $158,276 $163,473 $314,135 $321,939
Cost of sales 74,325 82,939 147,371 161,676
Cost of sales,
acquisition-
transition - Note A 1,827 2,760 4,165 4,589
Gross profit 82,124 77,774 162,599 155,674
Selling and
administrative - Note B 53,559 58,123 106,091 116,497
Research and development 6,375 7,498 12,224 15,323
Other expense - Note C 2,576 1,584 4,476 2,154
62,510 67,205 122,791 133,974
Income from operations 19,614 10,569 39,808 21,700
Loss on early
extinguishment of debt - 678 - 678
Interest expense 3,571 4,675 7,330 9,541
Income before income taxes 16,043 5,216 32,478 11,481
Provision for income taxes 5,535 1,802 11,205 3,727
Net income $ 10,508 $3,414 $21,273 $7,754
Per share data:
Net Income
Basic $.36 $.12 $.73 $.28
Diluted .35 .12 .71 .27
Weighted average
common shares
Basic 29,494 28,061 29,301 28,068
Diluted 30,060 28,266 29,830 28,312
Note A - Included in cost of sales in the three and six months ended
June 30, 2005 are approximately $1.8 million and $4.2 million,
respectively, in acquisition-transition related costs. Included in cost of
sales in the three and six months ended June 30, 2006 are approximately
$2.8 million and $4.6 million, respectively, in acquisition-transition
related costs.
Note B - Included in selling and administrative expense in the three
and six months ended June 30, 2006 are approximately $0.8 million and $1.6
million, respectively, of share-based payment expense.
Note C - Included in other expense in the three months ended June 30,
2005 are the following: $0.7 million in environmental settlement costs,
$0.4 million in costs related to the termination of a product offering and
$1.4 million in acquisition-related costs. Included in other expense in the
six months ended June 30, 2005 are the following: $0.7 million in
environmental settlement costs, $0.9 million in costs related to the
termination of a product offering and $2.8 million in acquisition-related
costs.
Included in other expense in the three months ended June 30, 2006 are
the following: $0.6 million in costs related to the write-off of inventory
in settlement of a patent dispute and $1.0 million in acquisition-related
costs. Included in other expense in the six months ended June 30, 2006 are
the following: $0.6 million in costs related to the write-off of inventory
in settlement of a patent dispute, $0.1 million in costs related to the
termination of a product offering and $1.5 million in acquisition-related
costs.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
December 31, June 30,
2005 2006
Current assets:
Cash and cash equivalents $3,454 $5,080
Accounts receivable, net 83,327 80,920
Inventories 152,428 153,661
Deferred income taxes 12,887 12,341
Other current assets 3,419 3,902
Total current assets 255,515 255,904
Property, plant and equipment, net. 104,224 109,058
Goodwill and other intangible assets, net 527,053 527,406
Other assets 16,991 15,210
Total assets $903,783 $907,578
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $4,208 $3,053
Other current liabilities 57,924 58,987
Total current liabilities 62,132 62,040
Long-term debt 302,643 296,902
Deferred income taxes 62,554 65,597
Other long-term liabilities 23,448 25,982
Total liabilities 450,777 450,521
Shareholders' equity:
Capital accounts 202,810 197,785
Retained earnings 259,932 267,686
Accumulated other comprehensive loss (9,736) (8,414)
Total equity 453,006 457,057
Total liabilities and
shareholders' equity $903,783 $907,578
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(in thousands)
(unaudited)
Six months ended
June 30,
2005 2006
Cash flows from operating activities:
Net income $21,273 $7,754
Adjustments to reconcile net income
to net cash provided by operating activities:
Depreciation and amortization 15,282 14,670
Share-based payment expense - 1,585
Deferred income taxes 7,365 3,650
Sale of accounts receivable (3,000) -
Other, net (11,025) (194)
Net cash provided by operating activities 29,895 27,465
Cash flow from investing activities:
Purchases of property, plant,
and equipment, net (8,098) (10,247)
Payments related to business acquisitions
net of cash acquired (364) (2,458)
Proceeds from sale of equity investment - 1,205
Net cash used in investing activities (8,462) (11,500)
Cash flow from financing activities:
Payments on debt (28,979) (141,896)
Proceeds of debt 8,000 135,000
Payments related to issuance of debt - (1,260)
Net proceeds from common stock issued
under employee plans 13,020 1,238
Repurchase of common stock (7,759) (7,848)
Other, net (396) (572)
Net cash provided by financing activities (16,114) (15,338)
Effect of exchange rate change
on cash and cash equivalents (3,002) 999
Net increase in cash and cash equivalents 2,317 1,626
Cash and cash equivalents at beginning of period 4,189 3,454
Cash and cash equivalents at end of period $6,506 $5,080
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE UNUSUAL ITEMS
(In thousands except per share amounts)
(unaudited)
Three months ended
June 30,
2005 2006
Reported net income $ 10,508 $3,414
Acquisition-transition related costs
included in cost of sales 1,827 2,760
Write-off of inventory in settlement
of a patent dispute - 595
Environmental settlement costs 698 -
Termination of product offering 429 27
Other acquisition-related costs 1,449 962
Total other expense 2,576 1,584
Loss on early extinguishment of debt - 678
Unusual expense before income taxes 4,403 5,022
Provision (benefit) for income taxes on
unusual expense (1,519) (1,808)
Net income before unusual items $ 13,392 $6,628
Per share data:
Reported net income
Basic $0.36 $0.12
Diluted 0.35 0.12
Net income before unusual items
Basic $0.45 $0.24
Diluted 0.45 0.23
Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE UNUSUAL ITEMS
(In thousands except per share amounts)
(unaudited)
Six months ended
June 30,
2005 2006
Reported net income $ 21,273 $7,754
Acquisition-transition related costs
included in cost of sales 4,165 4,589
Write-off of inventory in settlement
of a patent dispute - 595
Environmental settlement costs 698 -
Termination of product offering 949 83
Other acquisition-related costs 2,829 1,476
Total other expense 4,476 2,154
Loss on early extinguishment of debt - 678
Unusual expense before income taxes 8,641 7,421
Provision (benefit) for income taxes on
unusual expense (2,981) (2,672)
Net income before unusual items $ 26,933 $ 12,503
Per share data:
Reported net income
Basic $0.73 $0.28
Diluted 0.71 0.27
Net income before unusual items
Basic $0.92 $0.45
Diluted 0.90 0.44
Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com/
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; or Investors - Julie Huang,
or Theresa Kelleher, both of Financial Dynamics, +1-212-850-5600,
for CONMED Corporation
|
